CONDENSED COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Hyperfine Convertible Preferred Stock	Liminal Convertible Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Common Stock Class A Common Stock	Common Stock Class B Common Stock
Balance at Dec. 31, 2020	$ (61,054)			$ 10,415	$ (71,469)
Balance (in shares) at Dec. 31, 2020		95,010,858
Balance at Dec. 31, 2020		$ 128,286
Balance (in shares) at Dec. 31, 2020						1,576,137
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,794)				(7,794)
Issuance of Series D convertible preferred stock, net of issuance costs		$ 30,461
Issuance of Series D convertible preferred stock, net of issuance costs (in shares)		14,171,333
Investment from 4Bionics, LLC	700			700
Exercise of stock options	49			49
Exercise of stock options (in shares)						41,958
Stock-based compensation expense	267			267
Balance at Mar. 31, 2021	(67,832)			11,431	(79,263)
Balance (in shares) at Mar. 31, 2021		109,182,191
Balance at Mar. 31, 2021		$ 158,747
Balance (in shares) at Mar. 31, 2021						1,618,095
Balance at Dec. 31, 2020	(61,054)			10,415	(71,469)
Balance (in shares) at Dec. 31, 2020		95,010,858
Balance at Dec. 31, 2020		$ 128,286
Balance (in shares) at Dec. 31, 2020						1,576,137
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(22,374)
Balance at Jun. 30, 2021	(87,308)			6,535	(93,843)
Balance (in shares) at Jun. 30, 2021		109,182,191	57,500,000
Balance at Jun. 30, 2021		$ 158,747	$ 9,350
Balance (in shares) at Jun. 30, 2021						1,688,847
Balance at Mar. 31, 2021	(67,832)			11,431	(79,263)
Balance (in shares) at Mar. 31, 2021		109,182,191
Balance at Mar. 31, 2021		$ 158,747
Balance (in shares) at Mar. 31, 2021						1,618,095
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(14,580)				(14,580)
Investment from 4Bionics, LLC	2,816			2,816
Conversion of Liminal Common stock			$ 9,350
Conversion of Liminal Common stock (in shares)			57,500,000
Conversion of Liminal Common stock	(9,350)			(9,350)
Conversion of Liminal Common stock (in shares)						(180)
Exercise of stock options	149			149
Exercise of stock options (in shares)						70,932
Stock-based compensation expense	1,489			1,489
Balance at Jun. 30, 2021	(87,308)			6,535	(93,843)
Balance (in shares) at Jun. 30, 2021		109,182,191	57,500,000
Balance at Jun. 30, 2021		$ 158,747	$ 9,350
Balance (in shares) at Jun. 30, 2021						1,688,847
Balance at Dec. 31, 2021	186,227			322,540	(136,320)	$ 5	$ 2
Balance (in shares) at Dec. 31, 2021						55,277,061	15,055,288
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(23,775)				(23,775)
Stock-based compensation expense	4,111			4,111
Balance at Mar. 31, 2022	166,563			326,651	(160,095)	$ 5	$ 2
Balance (in shares) at Mar. 31, 2022						55,277,061	15,055,288
Balance at Dec. 31, 2021	186,227			322,540	(136,320)	$ 5	$ 2
Balance (in shares) at Dec. 31, 2021						55,277,061	15,055,288
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(46,934)
Balance at Jun. 30, 2022	150,508			333,755	(183,254)	$ 5	$ 2
Balance (in shares) at Jun. 30, 2022						55,312,656	15,055,288
Balance at Mar. 31, 2022	166,563			326,651	(160,095)	$ 5	$ 2
Balance (in shares) at Mar. 31, 2022						55,277,061	15,055,288
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(23,159)				(23,159)
Issuance of restricted stock						19,220
Exercise of stock options	$ 2			2
Exercise of stock options (in shares)	16,375					16,375
Stock-based compensation expense	$ 7,102			7,102
Balance at Jun. 30, 2022	$ 150,508			$ 333,755	$ (183,254)	$ 5	$ 2
Balance (in shares) at Jun. 30, 2022						55,312,656	15,055,288